Onyx Shuts Down $10 Bln Offer - Presented by: The Aol. On Network

Shares of Onyx Pharmaceutical soaring after it received- and rejected a $10 billion takeover offer from biotech Amgen. Its shares were already up 31 percent over the past 12 months. Onyx says Amgen's offer of $120 a share is too low. That offer represents a premium of 38 percent based on Onyx's closing price on Friday. And Onyx may have a point. Deutsche Bank analyst Robin Karnauskas says in a note: "From our M&A valuation, we expect higher bids for Onyx of at least $140."



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
F $ 13.78 0.62 ▼ 4.31%
PBR $ 12.93 0.82 ▲ 6.77%
MSFT $ 46.13 1.11 ▲ 2.47%
AAPL $ 105.22 0.39 ▲ 0.37%
PBR/A $ 13.46 1.10 ▲ 8.90%
QQQ $ 98.62 0.80 ▲ 0.82%
BAC $ 16.72 0.12 ▲ 0.72%
VALE $ 11.16 0.33 ▲ 3.05%

As of 10/24/2014, 04:15 PM
More Most Active